Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
FDA Approves Osimertinib for Unresectable NSCLC
The US Food and Drug Administration (FDA) has approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for the treatment of locally advanced, unresectable non–small cell lung cancer (NSCLC) in certain adult patients. Specifically, the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor…
English